

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 March 2023 (02.03.2023)



(10) International Publication Number
WO 2023/025307 A1

(51) International Patent Classification:

C07D 491/048 (2006.01) C07D 495/04 (2006.01)
C07D 491/052 (2006.01) A61K 31/496 (2006.01)
C07D 491/147 (2006.01) A61P 35/00 (2006.01)
C07D 471/04 (2006.01) A61P 35/02 (2006.01)
C07D 471/00 (2006.01)

(21) International Application Number:

PCT/CN2022/115259

(22) International Filing Date:

26 August 2022 (26.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202111000443.7 27 August 2021 (27.08.2021) CN
202111447991.4 30 November 2021 (30.11.2021) CN
202210274490.9 18 March 2022 (18.03.2022) CN

(71) Applicant: **IMPACT THERAPEUTICS (SHANGHAI), INC** [CN/CN]; Room 603, No.3 Building, 111 Xiangke Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 201210 (CN).

(72) Inventors: **CAI, Sui Xiong**; Room 3302, No.2, Lane 667, Gaoqing West Road, Pudong New Area, Shanghai 200124 (CN). **TIAN, Ye Edward**; Room 2704, No.2, Lane 667, Gaoqing West Road, Pudong New Area, Shanghai 200124 (CN). **WANG, Xiaozhu**; Room 2506, Kingmo Center, No. 1698 Shuanglong Avenue, Jiangning District, Nanjing, Jiangsu 211106 (CN).

(74) Agent: **SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC**; 435 Guiping Road, Shanghai 200233 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,


TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF



(57) Abstract: Provided are substituted tricyclic compounds as PARP inhibitors and the use thereof. The compounds are represented by Formula (I) as below, wherein, the ring Z, Z1, Z2, A1, A2, A3, L and Cy are defined herein. The compounds of Formula (I) are PARP inhibitors and thus are useful in the treatment of diseases, disorders and conditions, such as cancer, responsive to the inhibition of PARP activity. Provided are also a pharmaceutical composition comprising the compound of Formula (I) and the use of the compound of Formula (I) in the preparation of a medicament for the treatment or prevention of diseases or conditions responsive to the inhibition of PARP activity.

WO 2023/025307 A1